Pulse Biosciences' nPulse Cardiac System Shows Strong Durability in Atrial Fibrillation Study — Pulse Biosciences, Inc.

Event summary

Pulse Biosciences presented late-breaking data from its nPulse Cardiac Catheter System study at Heart Rhythm 2026, showing 100% procedural success at 6 months and 96% at 1 year.
The study cohort expanded to 95 subjects at 6 months and 53 subjects at 12 months, with a low serious adverse event rate of 1.7%.
Key metrics included left atrial dwell time of 18.6 minutes, total procedure time of 60.2 minutes, and fluoroscopy time of 9.4 minutes.
The study was conducted across multiple European sites, including Na Homolce Hospital in Prague, Jessa Hospital in Hasselt, and Tor Vergata Hospital in Rome.

The big picture

Pulse Biosciences' positive clinical data for its nPulse Cardiac Catheter System underscores the potential of non-thermal ablation technology in treating atrial fibrillation. The study's strong durability and efficiency metrics position the company favorably in a competitive cardiac health market, where procedural success and patient safety are critical differentiators.

What we're watching

Clinical Efficacy: How the sustained procedural success rates will impact regulatory approval and market adoption of the nPulse system.
Procedural Efficiency: Whether the consistent procedural performance metrics can be maintained as the study scales to larger cohorts.
Market Differentiation: The pace at which Pulse Biosciences can position nsPFA technology as a superior alternative to existing atrial fibrillation treatments.